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Diﬀerentiation therapy by induction of tumor cells is an important method in the treatment of hematological cancers such as
leukemia. Tumor cell diﬀerentiation ends cancer cells’ immortality, thus stopping cell growth and proliferation. In our previous
study, we found that fucose-containing polysaccharide fraction F3 extracted from Ganoderma lucidum can bring about cytokine
secretion and cell death in human leukemia THP-1 cells. This prompted us to further investigate on how F3 induces the
diﬀerentiation in human leukemia cells. We integrated time-course microarray analysis and network modeling to study the F3-
induced eﬀects on THP-1 cells. In addition, we determined the diﬀerentiation eﬀect using Liu’s staining, nitroblue tetrazolium
(NBT) reduction assay, ﬂow cytometer, western blotting and Q-PCR. We also examined the modulation and regulation by F3
during the diﬀerentiation process. Dynamic gene expression proﬁles showed that cell diﬀerentiation was induced in F3-treated
THP-1 cells. Furthermore, F3-treated THP-1 cells exhibited enhanced macrophage diﬀerentiation, as demonstrated by changes in
cell adherence, cell cycle arrest, NBT reduction and expression of diﬀerentiation markers including CD11b, CD14, CD68, matrix
metalloproteinase-9andmyeloperoxidase.Inaddition,caspasecleavageandp53activationwerefoundtobesigniﬁcantlyenhanced
in F3-treated THP-1 cells. We unraveled the role of caspases and p53 in F3-induced THP-1 cells diﬀerentiation into macrophages.
OurresultsprovideamolecularexplanationforthediﬀerentiationeﬀectofF3onhumanleukemiaTHP-1cellsandoﬀeraprospect
for a potential leukemia diﬀerentiation therapy.
1.Introduction
Ganoderma lucidum (Reishi or Ling-Zhi) is more than just
an ordinary fungus; it has long been used in traditional
Chinese medicinal remedies and for promotion of health
and longevity, in many Asian countries. In addition, recent
studies showed that G. lucidum is used to prevent or treat
various human diseases such as allergy, hepatopathy, hyper-
tension and cancer [1–3]. Previous evidences showed that
polysaccharides extracted from G. lucidum have potential
anti-cancer eﬀects through the inhibition of cancer cell
growth, induction of cell diﬀerentiation and suppression
of angiogenesis [2, 3]. In this study, the biologically active
compounds originally isolated and puriﬁed from G. lucidum
were identiﬁed as polysaccharides, and the main fraction was
designated as F3. Studies have reported that F3 is capable
of inducing cytokine expression such as tumor necrosis
factor-α (TNF-α) and interleukin-1 (IL-1), immunoglobulin
production and cell death [4–6]. Since F3 activates a wide
range of cellular responses, a systematic investigation into
its molecular mechanisms would require a large-scale and
genome-wide technology, for example, using microarray
analysis to explore the cellular alteration and molecular
disturbances induced by F3.
Previous studies showed that speciﬁc gene mutations,
including lineage-speciﬁc genes and transcription factors2 Evidence-Based Complementary and Alternative Medicine
involved in normal hematopoietic diﬀerentiation, also par-
ticipate in the pathogenesis of leukemia [7, 8]. Hence, one
approach for treating leukemia is diﬀerentiation therapy
that outlines a treatment plan to eliminate maturation
blockage and allow cell diﬀerentiation to take place [9].
The induction of terminal diﬀerentiation represents an
alternative approach to the treatment of leukemia, which
would generate leukemia cells with limited replicate capacity
that ultimately undergo apoptosis [10]. Recently, a number
of compounds were screened; for example, diﬀerentiation
inducer all-trans retinoic acid (ATRA) is eﬀective for
leukemia treatment [11]. It was found that arsenic trioxide
(As2O3) synergizes with ATRA to enhance terminal diﬀer-
entiation, and tyrosine kinase inhibitor geﬁtinib markedly
activates ATRA-induced diﬀerentiation of myeloid cell lines
[12–14]. Other diﬀerentiation inducers of myeloid leukemia
cells have been well documented for leukemia therapy, such
as12-O-tetradecanoylphorbol-13-acetate(TPA)andvitamin
D3 [15, 16].
Here, we intend to ﬁnd out whether polysaccharides F3
extracted from Chinese herb G. lucidum also have similar
diﬀerentiation eﬀect on leukemia cells. THP-1, human
monocytic leukemia cells, have been used as an in vitro
macrophage diﬀerentiation model for a long time. In this
study, we considered dynamic gene expression and protein
activation in F3-treated THP-1 cells at diﬀerent time points.
Through a systems biology approach, we gathered data on
possible eﬀects induced by F3, which were veriﬁed and
conﬁrmed by various experiments. Finally, we combined the
results of this study with our previous work to demonstrate
plausible regulations involved in F3-induced leukemia cells,
including cell death and cell diﬀerentiation.
2. Methods
2.1. Antibodies and Chemicals. The tested mouse mono-
clonal antibodies (mAb) include CASP9 and p21 from
Upstate (Lake Placid, NY, USA), p53 from Zymed (Paisley,
UK). Rabbit polyclonal antibodies include CASP6 and β-
actin from Cell Signaling (Beverly, MA, USA), CASP8 from
SantaCruzBiotechnology(SantaCruz,CA,USA),myeloper-
oxidase (MPO) from Upstate. Goat polyclonal antibody
against the human matrix metalloproteinases-9 (MMP-9)
was purchased from Santa Cruz Biotechnology. Secondary
antibodies conjugated horseradish peroxidase raised against
mouse, rabbit, and goat were purchased from Abcam
(Cambridge, UK). PE-conjugated monoclonal antibodies to
CD11b and CD14 and PE-conjugated isotypic control were
purchased from BD Pharmingen (San Diego, CA, USA). The
pan-caspase inhibitor z-Val-Ala-Asp-ﬂuoromethyl ketone
(Z-VAD-FMK; R&D Systems, Abington, UK) and the p53
inhibitor piﬁthrin-α (PET-α; Sigma-Aldrich, St Louis, MO,
USA) were dissolved in dimethylsulfoxide (DMSO).
2.2. THP-1 Cell Culture, Puriﬁcation of Reishi Extract,
Isolation of the F3 Fraction of Reishi Polysaccharides, and
Microarray Gene Expression Proﬁle Analysis. F3 was isolated
from the water soluble residue of Reishi polysaccharide and
puriﬁed by gel ﬁltration chromatography using a Sephacryl
S-500 column (95 × 2.6cm) with 0.1N Tris buﬀer (pH
7.0) as the eluent. The carbohydrate composition analyses
of F3 indicated that glucose (58.1%), mannose (15.1%)
and Galactose (13.5%) exist as the major components
together with smaller amounts of other sugars, including
fucose, N-acetylglucosamine, xylose and rhamnose. Detailed
experiments were performed according to our previous
report [6].
2.3. Signiﬁcant Functional Networks and Biological Path-
way Annotations. The diﬀerentially expressed genes were
annotated by Ingenuity Pathway Analysis (IPA; Ingenuity
Systems, Redwood City, CA, USA). In brief, the identiﬁed
genes were mapped onto available functional networks and
speciﬁc biological pathways, and then ranked by score. The
score is based on a P-value calculation; for example, if the
score is 3, then the corresponding P-value is 10−3, meaning
there is a 1/1000 chance that the focus genes are in a
network due to random chance. The signiﬁcance of the
association between the data set and the canonical pathway
was measured in two ways, ratio and P-value. Ratio is
displayed as the number of genes from the data set that map
to the pathway divided by the total number of genes that
map to the canonical pathway. Fischer’s exact test was used
to calculate a P-value determining the probability that the
association between the genes in the dataset and the canon-
ical pathway is explained by chance alone. The statistical
analysis of biofunctions and disturbed pathways were sorted
on the order of matching signiﬁcance by using IPA web
tool.
2.4. Morphologic Changes and Quantiﬁcation of Adherent
Cells. Under normal culture conditions THP-1 cells remain
in suspension; however, after treatment with F3 a sub-
population of cells becomes adherent within 24 or 48h.
Morphologic changes of the adherent cells were assessed by
Liu’s staining under phase contrast microscopy. In addition,
the supernatants were then collected in 15-ml tubes and
the plates were washed three times with PBS and combined
with the supernatant. The unattached cells were centrifuged,
resuspendedin200μl,andcountedinordertodeterminethe
adherence with a hemacytometer.
2.5. NBT Reduction Assay. Nitroblue tetrazolium (NBT;
Sigma)canbeusedtodeterminetheamountsofintracellular
O2− producedbyphagocyticcells.Thus,thisassayissensitive
enough to measure, quantitatively, even the small amounts
of O2− produced in macrophages. For NBT assay, cells were
seeded in 24-well plates at a density of 2 × 105 cells/ml
and incubated with or without F3. Diﬀerent numbers of
cells attached to a 24-well culture plate were incubated with
200μl RPMI-1640 medium containing 1mg/ml NBT and
4μg/ml phorbol 12-myristate 13-acetate (PMA; Sigma) and
then incubated at 37◦C for 1h. After incubation, cells were
washed twice with warm PBS, and then pelleted. The pellets
were resolved in 100μl DMSO. Absorbance at 570nm was
detected with spectrometer.Evidence-Based Complementary and Alternative Medicine 3
2.6. Cell Cycle Analysis. At o t a lo f1× 106 cells were collected
into ice-cold PBS, and ﬁxed with ice-cold 70% ethanol in
P B Sf o ra tl e a s t2 4ha t4 ◦C. Cells were stained using 10 μg/ml
propidium iodide (PI) solution (Santa Cruz Biotechnology)
and RNaseA (Santa Cruz Biotechnology) in PBS in the dark
for at least 30min at room temperature. The percentages of
cells in the diﬀerent phases of the cell cycle was measured
with a FACS ﬂow cytometer (Becton Dickinson, San Jose,
CA, USA) and analyzed by using CellQuest software (Becton
Dickinson).
2.7. Western Blot. Western blot was performed as previously
described [6]. Brieﬂy, F3-treated and untreated THP-1 cells
were washed with PBS twice. Cell pellets (1 × 107 cells)
were solubilized in lysis buﬀer containing 7M urea, 4%
CHAPS,2Mthioureaand0.002%bromophenolblue.Lysates
were centrifuged at 13200g for 30min. Proteins were loaded
into 10% SDS-PAGE and transferred onto polyvinylidene
diﬂuoride membranes (Millipore, Bedford, MA, USA) at
150V for 1.5h. After blocking in 5% non-fat milk in PBST
containing 0.05% Tween 20 (Sigma) at room temperature
overnight with gentle rocking, membranes were probed with
antibodies. Membranes were incubated with corresponding
primary antibody overnight at 4◦C and then incubated
with secondary antibodies. After incubation with secondary
antibodies, immunoblots were visualized with the ECL
detection kit (Amersham Biosciences) and exposed to X-ray
ﬁlm. β-actin was used as an internal loading control.
2.8. Primer Design. Primers were designed based on the
published sequences in NCBI. We used Beacon Designer
to design the primers. Primers were designed to meet the
following requirements: 75–150bp in length, 50–60% in CG
content, less than 5 degrees Tm diﬀerence between forward
and reverse primers, limited GC repeats, amplicons between
80–120bp, and limited dimer and hairpin formation. The
genes and primers used for RT-PCR and real-time PCR are
performed using the following primer sets: CD11b (for-
ward: 5 -CAAGGAAGCCGGAGAGGTCAGA-3 ; reverse:
5 -CGG AGT CCA GAG CCA GGT CAT AAG-3 ); CD14
(forward: 5 -CACAGCCTAGACCTCAGCCACAAC-3 ;
reverse: 5 -CCA GCC CAG CGAACG ACAG-3 ); CD68
(forward: 5 -CAC CTC CAA GCC CAG ATTCAG AT-3 ;
reverse: 5 -CCTTGGTTTTGTTGGGGTTCAGTA-3 );
MPO (forward: 5 -CTTCGTCACTGGCGTCAACTG-3 ;
reverse: 5 -AGGAGCGGAAGAACGGGATG-3 ); MMP-
9(forward:5  -ACCAAGTGGGCTACGTGACCTATG-3 ;
reverse: 5 -GTATCCGGCAAACTGGCTCCTT-3 ).
2.9. Quantitative Real-Time PCR. Detection of gene expres-
sion by qualitative real-time PCR (Q-PCR) was determined
essentially.Brieﬂy,totalRNAwereisolatedfromcelllinesand
ﬁrst-strand cDNA synthesis was generated. Extracted ﬁrst-
strand cDNAs were analyzed using a BioRad iCycler iQ Real-
Time Detection System with SYBR Green dye (Molecular
Probes, Eugene, OR, USA). SYBR Green yields a strong
ﬂuorescentsignalonbindingdouble-strandedDNAenabling
the quantiﬁcation of gene expression by measurement of the
intensity of the ﬂuorescent light. mRNA expression of these
genes were normalized to RNA content for each sample by
using β-actin gene products as internal controls. A standard
curve was also run in each PCR reaction. Fold changes
were calculated using the ΔΔCt method with β-actin as the
referencegeneampliﬁedfromthesamples.Allreactionswere
runintriplicate.Thereactionproductswereseparatedon2%
agarose gel and stained with ethidium bromide for product
length check.
2.10. Flow Cytometry. The surface expression of macrophage
diﬀerentiation marker CD11b and CD14, or binding of PE-
conjugated mouse IgG2a was determined by ﬂow cytometric
analysis as previously described [17]. The harvested cells
were washed with PBS followed by incubation with the PE-
conjugated anti-human CD11b and CD14 for 1h. For each
marker, a total of 10000 events were collected from the
gated area detecting viable cells. The results were collected
as either percentage of positive cells or mean ﬂuorescence
intensity (MFI) values subtracted by the MFI of isotype
control antibody-stained cells. The ﬂow cytometric analysis
was performed on the FACS system, and the data were
analyzed using CellQuest software. The isotype control PE-
conjugated mouse IgG2a mAb-stained cells were used as the
background control in all experiments.
2.11. Statistical Analysis. Results are shown as mean ± SD
from more than three independent experiments. The two-
tailed Student’s t-test was used to compare diﬀerent groups.
Values of P<. 05 were considered signiﬁcant.
3. Results
3.1. Signiﬁcant Functional Networks and Biological Pathways
Involved in F3-Induced THP-1 Cells. In a prior study, G.
lucidumpolysaccharideshavebeenusedasactivecompounds
for immuno-modulation and to display anti-tumor activity;
little attention has been paid to its eﬀect on the process
of cancer cell diﬀerentiation [18]. Here, we used high-
throughputmicroarraytoscreenandinvestigatethedynamic
patterns of gene expression and analyzed possible biological
functions and physiological role of F3-treated leukemia cells
through a bioinformatics approach. All the diﬀerentially
e x p r e s s e dg e n e sw e r ei d e n t i ﬁ e da n da r es h o w e di nS u p p l e -
mentary Tables S1 and S2. We have submitted the array data
to the GEO database and the series record is GSE16014.
In order to study the eﬀects induced by F3, we identiﬁed
the gene expression patterns by oligonucleotide microarray
analysis. Genes with more than 2-fold change in expression
levels between control and F3-treated THP-1 cells were
sorted into categories according to their annotation in IPA.
The IPA knowledge-based database provides annotations
regarding biological functions and signaling. There were 115
and 96 signiﬁcant genes associated with cell diﬀerentiation
after F3 treatment for 6 and 24h, respectively (Figure 1(a)).
Furthermore, these signiﬁcant genes were selected for map-
ping signiﬁcant functional protein-protein interaction net-
works (Figure 1(b)). The top ﬁve signiﬁcant protein-protein4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: F3-induced gene expression proﬁles in THP-1 cells associated with cell diﬀerentiation were analyzed by the IPA tool. (a) Molecules
involved in the process of cell diﬀerentiation are presented. (b) Interaction network analysis as a framework for the interpretation of cell
diﬀerentiation was performed. This shows the major functional networks (c) and biological pathways (d) that were found to be signiﬁcantly
associated with cell diﬀerentiation (P<. 05).
interaction networks aﬀected by F3 were chosen for further
analysis (Supplementary Table S3). These networks describe
the functional relations between gene products based on
known interactions. The observed signiﬁcant networks were
associated with cell death and cellular development. On the
basis of these selected networks, a total of 10 biological
functions were found to be highly signiﬁcant, the main
one being cellular development, which depicts functions
associated with the development and diﬀerentiation of cells
(Figure 1(c)). Moreover, we used the IPA tool to connect
these networks with known biological pathways. Signiﬁcant
biologicalpathwayshighlyassociatedwithcelldiﬀerentiation
are shown in Figure 1(d). For example, IL-6 signaling
regulates cell diﬀe r e n t i a t i o na sw e l la sc e l lg r o w t ha r r e s t
through the activation of transcription factor STAT3 [19].
NF-κB signaling plays a critical role in the development
a n df u n c t i o no fa l lh e m a t o p o i e t i cc e l lt y p e s[ 20]. Induction
of GM-CSF signaling eﬀectively diﬀerentiates monocytes
to a more macrophage-like phenotype [21]. Interestingly,
the disturbed pathways in F3-treated THP-1 cells closely
resembledthecanonicalpathwaysfoundoutindiﬀerentiated
macrophages derived from GM-CSF-treated blood mono-
cytes [22]. Therefore, the dynamic gene expression proﬁling
provides a feasible approach to discover cell diﬀerentiation
pathways which involved in F3-induced leukemia cells.
3.2.Leukemia Cells DiﬀerentiationintoMacrophage-LikeCells
Induced by F3. The potential role of G. lucidum polysaccha-
rides F3 in cell diﬀerentiation was also studied. THP-1 cells
were treated with 30μg/ml of F3 for diﬀerent time courses.
Cell adhesion, a hallmark of macrophage diﬀerentiation, was
examined under a phase-contrast microscope. Adhesive and
non-adhesive cells were counted by trypan blue exclusion.
The treatment of F3 greatly changed the cell morphology
and increased leukemia cell adherence (Figure 2(a)). In the
presence of F3, about 45% of THP-1 cells were observed to
be attached to the culture wells, and macrophage-like cell
patterns were observed by Liu’s staining (Figure 2(a)). These
dataprovideaperspectivethatG.lucidumpolysaccharidesF3
might have the potential to induce diﬀerentiation. To further
examine the eﬀects of F3 on leukemia cell diﬀerentiation, we
appliedthefollowingassays.First,F3-induceddiﬀerentiation
of leukemia cells was determined by NBT reduction assay,
a functional marker to evaluate the ability of superoxide
production during macrophage diﬀerentiation [23]. Our
data show that F3 greatly enhances superoxide production
after 24h of treatment, as demonstrated by the presence
of intracellular purple formazan deposit (Figure 2(b)). Fur-
thermore, time-course study observed signiﬁcant increase in
the levels of NBT reduction, indicating that F3 was capable
of enhancing NBT reduction (Figure 2(b)). Previous studies
revealed that irreversible arrest in the cell cycle is a hallmark
of terminally diﬀerentiated myeloid cells [24]. Therefore, we
analyzedtheeﬀectofF3oncellcycleprogression inleukemia
cells. As shown in Figure 2(c) with F3 treatment, THP-1 cell
population at G0/G1 phase increased from 46 to 80%. These
data demonstrate that F3 is able to induce cell cycle arrest
in leukemia cells. These results showed that F3 can induce
leukemia cells diﬀerentiation to macrophage-like cells.
3.3. F3-Induced Expression of Speciﬁc Macrophage Diﬀerenti-
ation Markers. To make certain that F3 alone was suﬃcient
for macrophage diﬀerentiation to occur, we analyzed speciﬁc
cell markers and enzyme activity related to macrophage
diﬀerentiation. As shown in Figure 3(a), the gene expres-
sion levels of CD11b, CD14 and CD68 were markedly
elevated in F3-induced THP-1 cells. The enzyme MPO is
synthesized only in myeloid and monocytic cells; therefore,
downregulation of MPO activity is a characteristic feature in
macrophage diﬀerentiation, making it an important marker6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Potential of F3-induced leukemia cells to diﬀerentiate into macrophages. (a) Eﬀect of F3 on cell adherence is shown under
phase-contrast microscope. THP-1 cells were incubated with/without 30μg/ml of F3, and macrophage-like cells were shown by Liu’s stain.
Quantiﬁcation of cell adherence is shown in the lower panel where the percentage of adhesive THP-1 cells is presented. The data were shown
as mean ± SD from three independent experiments. (b) F3 treatment was able to increase NBT reduction signiﬁcantly. NBT reduction assay
showed insoluble and visible blue formazan precipitates in F3-treated THP-1 cells. The blue formazan precipitates in F3-treated THP-1 cells
were measured by absorbance at 570nm. The data were shown as mean ± SD from three independent experiments. Individual Student’s t-
test was performed between F3-treated leukemia cells and untreated control (∗∗P<. 001). (c) Summary of cell cycle analysis is shown in this
panel where the percentage of leukemia cells in each cell-cycle phase is shown. The data were shown as mean ± SD from three independent
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Figure 3: Expression of macrophage diﬀerentiation markers in F3-induced THP-1 cells were examined by Q-PCR and western blotting.
(a) Gene expressions of classical markers of macrophage diﬀerentiation, CD11b, CD14 and CD68, were determined by Q-PCR. (b) Other
macrophage diﬀerentiation markers, MPO and MMP9, were also determined by Q-PCR and western blotting. mRNA expression of these
geneswasnormalizedtoRNAcontentforeachsamplebyusingβ-actinasinternalcontrols; β-actinwasalsousedasinternalloadingcontrols
in western blotting.
of the myeloid lineage [25]. Here, F3 treatment reduced
both overall MPO mRNA level and MPO protein activity
in THP-1 cells (Figure 3(b)). Previous reports indicated that
matrix metalloproteinase-9 (MMP-9) is produced during
the macrophage diﬀerentiation process [26]. Initially, both
MMP-9 mRNA expression and MMP-9 protein activity were
not detected in THP-1 control; however, MMP-9 mRNA and
protein production were identiﬁed in F3-treated THP-1 cells
(Figure 3(b)). Furthermore, we examined the expression
levels of the speciﬁc macrophage markers by ﬂow cytometric
analysis. Our data showed that treatment of THP-1 cells with
F3 for 24 and 48h could induce a signiﬁcant increase in the
expression of CD11b and CD14 (Figure 4). Taken together,
these data indicate that leukemia cells would diﬀerentiate
into macrophages after F3 treatment. These results were also
consistent with the gene expression proﬁles explored using
the IPA tool.
3.4. Regulation of F3-Induced Macrophage Diﬀerentiation
via Caspase Cleavage and p53 Activation. Our previous
studies demonstrated that F3 is able to induce apoptosis
via the death receptor pathway. Caspase 3 and 7 were
cleaved into their active form in F3-treated THP-1 cells,
while several lines of evidence indicated that active caspase8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Flow cytometry detection of CD11b and CD14 expression in leukemia cells upon treatment with F3. The results were collected
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cleavage also contributes to the diﬀerentiation of monocytes
into macrophages [6, 27, 28]. However, caspase activation
does not involve the diﬀerentiation into dendritic cells,
indicating that the diﬀerentiation is lineage-speciﬁc [27].
To investigate whether caspases were activated during the
diﬀerentiation process in this study, we studied the time-
dependent appearance of caspase cleavage fragments by
western blotting. Combining our previous data, we also
observed the presence of caspase-8 and caspase-9 in their
active forms in F3-treated THP-1 cells, indicating that
caspases cleavage might be involved in this diﬀerentiation
process (Figure 5(a)). One thing worth noting was that the
cleavageofcaspase6wasnotnoticeablyseen,possiblyimply-
ing its minor contribution to macrophage diﬀerentiation.
Moreover, several in vitro and in vivo assays have shown
that p53 expression in undiﬀerentiated cells could result in
cells moving into a diﬀerentiated state [29, 30]. Generally,
p21 can be transcriptionally activated by wild-type p53, and
the induction of p21 expression has been shown in several
systems to lead to in vitro diﬀerentiation [31]. In this study,
we examined the expression of p53 and its downstream
molecule p21 by western blotting. The result showed thatEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: Cells were treated with F3, and then cell lysates
were obtained for western analyses to observe the expressions
of macrophage diﬀerentiation-associated protein. Detection of (a)
caspase cleavage and (b) p53/p21 was determined by western
blotting.
treatment of THP-1 cells with F3 could elevate p53 and
p21 expressions and thus lead to macrophage diﬀerentiation
(Figure 5(b)). Here, we identiﬁed the activation of p53 and
severalcaspasescleavageinTHP-1cellsthatcontributetothe
diﬀerentiation into macrophages in response to F3.
To further elucidate the eﬀects of caspase cleavage
and p53 activation on macrophage diﬀerentiation in F3-
treated THP-1 cells, caspase and p53 inhibitors were applied.
Figure 6(a) shows that the presence of general caspase
inhibitor Z-VAD-FMK alone did not induce the expression
of diﬀerentiation markers while it reduced the appearance
of F3-induced CD14 positive cells and blocked CD11b
expression levels in a dose-dependent manner. Our previous
study showed that apoptotic events were initiated via the
death receptor signaling after F3 treatment in THP-1 cells.
The function of F3 is rather complex as it may involve
v a r i o u sb i o l o g i c a le ﬀects. Our published work suggested
that F3 might mimic/induce death receptor ligands, such as
TNF-α and tumor necrosis factor-related apoptosis inducing
ligand (TRAIL), to initiate signaling in THP-1 cells, and a
recent study clariﬁed that caspase activation mediates TRAIL
cytotoxicity and monocytic maturation of HL-60 cells [32].
Accordingtoourstudy,F3couldinfactenhancemacrophage
diﬀerentiation of leukemia cells THP-1 and mimic/induce
TRAIL to trigger apoptosis through the caspase cascade. The
eﬀects of PET-α, a chemical inhibitor of p53 transcriptional
activity, on macrophage diﬀerentiation were similar to the
presence of caspase inhibitor (Figure 6(b)). PET-α signiﬁ-
cantly reduces the percentage of THP-1 cells expressing cell
surface markers, that is, CD11b and CD14, in response to
F3 in a dose-dependent manner; PET-α also decreases the
expression levels of CD11b and CD14 in F3-treated THP-
1 cells. These results showed that caspase cleavage and p53
activation can contribute to the macrophage diﬀerentiation
in F3-treated THP-1 cells.
4. Discussion
For understanding more about molecular regulation and
gene expression proﬁles, we used the high-throughput
screeningmethod, microarraychipandbioinformaticstools,
to investigate the dynamic gene expression patterns and
related molecular mechanisms. In our previous study, func-
tional networks associated with cell death and the pathwayof
apoptosisinductionthroughDR3andDR4/5deathreceptors
were found to be signiﬁcant in F3-treated THP-1 cells for 6
and 24h [6]. We further observed irregular and rough edges
of cell membrane under the phase-contrast microscope,
incremental to the chromatin condensed cells, and signs
of phosphatidylserine release. These results indicated that
cell shrinkage happened and somehow apoptosis followed.
Recentstudies alsoshowed G.lucidum to induceapoptosis in
many cancer cells such as lung cancer cells, colon carcinoma
cells, prostate cancer cells and breast cancer cells. In our Q-
PCRgeneexpressionresults,CASP8showedasigniﬁcantup-
regulated expression. Caspase 8, 3, 7 were also cleaved into
their active forms after F3 treatment. Our previous results
suggestedthatF3mightmimic/inducedeathreceptorligands
such as TNF-α and TRAIL to initiate signaling via death
receptor oligomerization, recruitment of specialized adaptor
proteins and the activation of caspase cascade, followed by
cell shrinkage and apoptosis [6].
In addition to cell death eﬀect, cell diﬀerentiation was
also important in F3-treated THP-1 cells (Figure 1). Such
an eﬀect of F3 on cell diﬀerentiation was conﬁrmed by
change of cell morphology from monocytic phenotypes
to macrophage-like cells and the elevated cell adherence
percentage as well (Figure 2(a)). Another two assays, NBT
reduction and cell cycle analysis, suggest the eﬀect of
diﬀerentiation to macrophage-like cells. F3 treatment for
24 and 48h increased NBT reduction activity markedly
(Figure 2(b)) and together with arrest in the G0/G1 phase
of the cell cycle (Figure 2(c)). Crucially, up-regulation of
CD11b, CD14, CD68 and MMP-9, and downregulation of
MPO, strongly suggested the eﬀect of macrophage diﬀerenti-
ation in F3-treated THP-1 cells (Figures 3 and 4).
Previous reports showed that protein cleaved by caspase
c o n t r i b u t e st om a c r o p h a g ed i ﬀerentiation process [27, 28].
However, caspase activation does not involve in diﬀer-
entiation into dendritic cells, indicating that speciﬁc lin-
eage diﬀerentiation is determined by these enzymes [27].
Here, caspase cleavage was identiﬁed during macrophage
diﬀerentiation in F3-treated THP-1 cells (Figure 5(a))a n d
general eﬀector caspase inhibitor blocked the expres-
sion of macrophage diﬀerentiation markers (Figure 6(a)).10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: The eﬀects of caspase inhibitor (Z-VAD-FMK) or p53 inhibitor (PET-α, and F3 alone or in combination with inhibitors, on the
diﬀerentiation of THP-1 cells into macrophages were observed by ﬂow cytometry analysis. (a) Caspase inhibitors (6, 20, 50μM) or (b) p53
inhibitors (5, 50, 100μM) were added to either the control or F3-treated cultures after 24h of incubation. The percentage of CD11b and
CD14 positive cells and MFI of CD11b and CD14 positive cells were shown as the mean ± SD, and individual Student’s t-test was performed
between F3-treated THP-1 cells and caspase inhibitor combined with F3 co-cultured groups (∗P<. 01, ∗∗P<. 001) in comparison to
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Figure 7: A proposed model to characterize the intricate machinery in F3-induced THP-1 cells. F3 might mimic/induce death receptor
ligands such as TNF-α and TRAIL to trigger apoptosis and macrophage diﬀerentiation of leukemia cells THP-1 through caspase cascade and
p53-dependent pathway.
Interestingly, caspase activation is required for the diﬀer-
entiation of monocytes into macrophages and occurs in
the absence of apoptosis feature, while our previous studies
showed apoptotic events were initiated via death receptor
signaling after F3 treatment in THP-1 cells. Therefore, F3-
induced cell diﬀerentiation associated with cell death gives
unlike account from TPA induction of macrophage diﬀer-
entiation without apoptotic features [27]. Our published
work has suggested that F3 might mimic/induce death
receptor ligands such as TNF-α and TRAIL to initiate
signaling in THP-1 cells, and a recent study has clariﬁed
that caspase activation mediates TRAIL cytotoxicity and
monocytic maturation of HL-60 cells [32]. We suggest that
F3 could in fact mimic/induce TRAIL to trigger apoptosis
and macrophage diﬀerentiation of leukemia cells THP-1
through caspase cascade.
It was indicated in several experimental models that
wild-type p53 and p21 facilitate cellular diﬀerentiation of
various cell types, including the regulation of monocytic
maturation as well [29, 30]. Treatment of F3 in THP-1 cells
could gradually enhance p53 and p21 expressions during
macrophage diﬀerentiation (Figure 5(b)), and inhibition of
p53 activity could reduce the expression of macrophage
diﬀerentiation markers (Figure 6). Additionally, p53 and p21
activities might partially contribute to the accumulation of
cell cycle progression in the G0/G1 phase. The previous
study indicated that cell cycle arrest and cell diﬀeren-
tiation are determined via the p53-dependent pathway
[30].
Studies have reported that F3 is capable of induc-
ing cytokine expression such as TNF-α and IL-1 and
immunoglobulin production [4, 5]. In our study, we have
examined two dominant eﬀects caused by F3, cell death and
cell diﬀerentiation. We proposed a model to characterize
the intricate machinery in F3-induced THP-1 cells, as
illustrated in Figure 7. Our study showed that F3 might
exhibit anti-tumor activity based upon the induction of
diﬀerentiation and apoptosis. The anti-tumor activity of F3
maybesimilartotheTPA-diﬀerentiatedHL-60cellsfollowed
by subsequent cell death [33]. Apoptosis might be observed
as a consequence of terminal diﬀerentiation.
In summary, we integrated dynamic gene expression pat-
terns and protein activation proﬁle to infer possible regula-
tionsinvolvedinF3-inducedmacrophagediﬀerentiation.We
suggest that F3 could induce leukemia cells diﬀerentiation to
macrophages, as demonstrated by enhancing the percentage
of cell adherence, superoxide production, cell cycle arrest
and expression of diﬀerentiation markers. The results in this
study revealed the molecular regulatory mechanism of F3
involved in human leukemia cell diﬀerentiation and F3 can
be a potent natural compound for leukemia diﬀerentiation
therapy.
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